Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Pfizer Pfriends" Average Discount Rx Prices Available Via Toll-Free Number

This article was originally published in The Pink Sheet Daily

Executive Summary

Enrollment in the drug discount card program has begun through Pfizer's "Helpful Answers" website. The company will provide average expected discounts for specific drugs, as well as participating pharmacies, through its toll-free number.

You may also be interested in...



"Pfizer Pfriends" Discount Program Offers Medicare Card Model To Uninsured

The company will provide discounts through a two-tiered structure to people who lack drug coverage, regardless of age or income level. The discounts range from 15% to 37% off of retail prices for Pfizer products. Pfizer will publicize the discounted prices via a website and call center that will launch in August.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says

Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel